Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June,...
Day: November 13, 2023
Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
On track to report topline week 52 liver biopsy results from Phase 2b FASCINATE-2 trial with denifanstat in the first...
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
Successful End-of-Phase 2 Meeting with FDA for Oral APX3330; Agreement on Phase 3 Registration Endpoint RYZUMVI™ Approved by FDA; Ocuphire...
New Randomized Controlled Trial Demonstrates the Efficacy of Daxor’s BVA Guided-Care in Heart Failure Patients
Data From Study Funded by NIH Presented at the American Heart Association Annual Meeting Oak Ridge, TN, Nov. 13, 2023...
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
Efzofitimod demonstrated immune regulatory function improving disease outcomes and mitigating fibrosis in animal models.SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE)...
Immunovant to Present at Upcoming Investor Conferences
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal...
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that...
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update
19 subjects enrolled in the OPMD Natural History Study, with multiple subjects entering the eligibility period this year for entry...
Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression
Results Suggest Formulation Potentially Suitable for At-Home Administration Ketabon Also Releases In-Depth Data from Phase 2 KET01 Trial MUNICH, Germany,...
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
-- BROADWAY Phase 3 trial enrollment completed; on-track to report topline data for Phase 3 BROOKLYN and BROADWAY trials in...
Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic...
Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
$12.9 Million in Cash and Investments as of September 30, 2023;Runway Expected to Reach Meaningful Development Milestones On Track to...
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 ----...
Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results
- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on...
IO Biotech Appoints Helen Collins, MD, to its Board of Directors
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating...
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on...
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
Announced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104 Completed $7.5 Million Private Placement Equity...
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
Company maintains strong cash position of $184.8 millionSOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc....
BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2023
Data Show that BIV201 in Combination with Standard of Care (SOC) is Well Tolerated with No Major Difference in Treatment-Emergent...